45
Santen Pharma
4536.T·TSEOsaka JPFounded 18904,000 employees
Mid CappharmaPublicOphthalmology
Platform: Ophthalmic Spec
Market Cap
$6B
All Drugs
4
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (4536.T)
Loading 4536.T stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Cevisertib | 453-8723 | Phase 2/3 | 1 | SOS1 | Thymoma | ||
| 453-4974 | 453-4974 | NDA/BLA | 1 | PLK4 | MSMCC | ||
| 453-4569 | 453-4569 | Phase 2/3 | 2 | MET | Parkinson's | ||
| 453-180 | 453-180 | Phase 3 | 2 | TIM-3 | AS |
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Santen Pharma trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (7)